Soleno Therapeutics (SLNO) Posts Earnings Results, Misses Expectations By $0.08 EPS

Soleno Therapeutics (NASDAQ:SLNO) issued its quarterly earnings data on Wednesday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.08), Bloomberg Earnings reports.

Soleno Therapeutics opened at $1.85 on Friday, according to MarketBeat. Soleno Therapeutics has a 52 week low of $1.76 and a 52 week high of $1.77.

In other news, major shareholder Larry N. Feinberg bought 50,000 shares of Soleno Therapeutics stock in a transaction that occurred on Tuesday, May 15th. The shares were acquired at an average price of $1.80 per share, with a total value of $90,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 69.75% of the stock is owned by corporate insiders.

A number of equities research analysts recently issued reports on the company. Noble Financial set a $4.00 price objective on Soleno Therapeutics and gave the stock a “buy” rating in a research report on Wednesday. Maxim Group set a $4.00 target price on Soleno Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Finally, ValuEngine raised Soleno Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development.

Earnings History for Soleno Therapeutics (NASDAQ:SLNO)

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply